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Abstract
Proliferative verrucous leukoplakia (PVL) is a rare form of oral leukoplakia, which was first described in 1985 by 
Hansen et al. Since then, various published case series have presented PVL as a disease with aggressive biological 
behaviour due to its high probability of recurrence and a high rate of malignant transformation, usually higher 
than 70%. PVL is a long-term progressive condition, which is observed more frequently in women and elderly 
patients over 60 years at the time of diagnosis. Eventually, PVL tends to become multifocal with a progressive 
deterioration of the lesions, making it more and more difficult to control. Tobacco use does not seem to have a 
significant influence on the appearance or progression of PVL. These lesions may occur both in smokers and non-
smokers. Nevertheless, at present, the aetiology of PVL remains unclear as well as its management and diagnosis, 
which is still retrospective, late and poorly defined, lacking consensus criteria.
Therefore, the aim of this study is to propose a set of diagnostic criteria to allow for the early and objective iden-
tification of PVL cases, and thereby conduct an adequate management. The proposal includes five major criteria 
and four minor criteria, as well as specific combinations among them in order to establish a correct and objective 
diagnosis of proliferative verrucous leukoplakia.
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Introduction
White lesions are relatively frequent in the oral cavity 
with a prevalence of approximately 24.8%, according to 
Axéll (1). Among them is oral leukoplakia with a preva-
lence rate of 0.2 to 3.6% (1-5). Petti reported an esti-
mated world leukoplakia prevalence of 2% (6), while for 
van der Waal a rate of 0.5% or lower is more realistic 
given geographical variations (7).
Leukoplakia was described by the World Health Organ-
ization as a “Precancerous Lesion” (8). However, more 
recently it has been suggested that the terms “premalig-
nant” and “precancerous” should be substituted for “po-
tentially malignant”, and that all precancerous lesions 
and conditions should be grouped under the common 
name of “potentially malignant disorders” (9). Follow-
ing the latest Workshop on oral precancer organized in 
2005 by the World Health Organization Collaborating 
Centre for Oral Cancer, oral leukoplakia should be de-
fined as “a white plaque of questionable risk having ex-
cluded (other) known diseases or disorders that carry no 
increased risk for cancer” (7,9). Despite these modifica-
tions in its nomenclature and classification, oral leuko-
plakia remains the most frequent potentially malignant 
disorder in the oral cavity. Its malignant transformation 
rate varies from 0.13 to 17.5%, according to the pub-
lished data (10-12), with a reported annual malignant 
transformation rate of approximately 1% for all types of 
oral leukoplakia (7,13).
Barely a few decades ago, a rare form of oral leukopla-
kia known as proliferative verrucous leukoplakia (PVL) 
was first reported. It presents specific characteristics, 
mainly a more aggressive biological behaviour than 
other forms of leukoplakia expressed by: a tendency to-
wards multifocality; a high probability of recurrence; 
and a high rate of malignant transformation, which can 
range between 40 and 100% in a follow-up period of 4.4 
to 11.6 years (14-20).
PVL was first described in 1985 by Hansen et al. as a 
long-term progressive condition (sometimes more than 
20 years) which develops initially as a white plaque of 
hyperkeratosis that eventually becomes a multifocal 
disease with confluent, exophytic and proliferative fea-
tures. The lesions are slow-growing yet persistent, as 
well as irreversible and resistant to all forms of treat-
ment with a high recurrence rate. Throughout its de-
velopment, it is common to find erythematous and/or 
verrucous areas that occasionally progress to verrucous 
carcinoma or squamous cell carcinoma (SCC), and fre-
quently to several of them (14).
As reported in previous case series regarding PVL, wom-
en (21) are affected more often than men. There is prob-
ably no racial preference (22). The mean age at the time 
of diagnosis is over 60 years. Tobacco use does not seem 
to have a significant influence on the disease given that 
PVL occurs both in smokers and non-smokers (23). 
At present, the aetiology of PVL is unknown with-
out widely accepted diagnostic and treatment criteria 
(23,24). This hinders the correct treatment of PVL pa-
tients as well as the advance in the knowledge about 
the disease, given that researchers do not use equiva-
lent criteria and the studies are, thus, hardly compara-
ble (23,24). Generally, diagnosis is made according to 
Hansen’s first definition of PVL in 1985, not taking into 
account the latter ones. This creates doubt about wheth-
er all published PVL cases are indeed PVL, as has been 
stated by several authors (22-24).
As a result of this, we find it necessary to elaborate spe-
cific diagnostic criteria for PVL.
Material and Method
A reference search was carried out for PVL studies 
published between 1985 and 2009. Keywords, both in 
Spanish and English, included: proliferative verrucous 
leukoplakia, multifocal leukoplakia, multiple leukopla-
kia and verrucous leukoplakia.
Only those studies which complied with at least one of 
the following criteria were selected:
- PVL case series, with a minimum of 7 cases for each 
series, involving at least seven of the following items: 
number of patients, age, gender distribution, tobacco 
consumption, follow-up period, lesion sites, treatments, 
recurrence rate, and malignant transformation rate.
- Literature reviews examining proliferative verrucous
leukoplakia, as well as studies regarding its histopathol
ogy, malignant transformation and diagnosis.
Analysing the published cases of PVL, the most fre-
quently observed clinical and histopathological data 
were identified, as well as those which were highly rel-
evant. These study data were then divided into major 
and minor diagnostic criteria, and later combined in dif-
ferent ways in order to find those that would facilitate a 
more objective and correct diagnosis of PVL.
Results
A total of 8 case series studies that complied with the 
aforementioned criteria were selected; as well as 5 lit-
erature reviews and 1 study on oral squamous cell car-
cinoma cases that developed from PVL lesions: Bagán 
et al. (25).
The results of the various case series are shown in table 
1. Among the found series, the authors of the study by 
Ghazali et al. (22)  were not able to confirm that their 
cases could be diagnosed as PVL. Therefore, this series 
was not included in the table. Thus, solely the results of 
7 case series are shown in it.
After analysing the published cases, 5 major and 4 mi-
nor criteria were proposed, as well as various combina-
tions among them, to allow for a definitive diagnosis of 
PVL. 
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Major Criteria (MC):
A. A leukoplakia lesion with more than two different 
oral sites, which is most frequently found in the gingiva, 
alveolar processes and palate.
B. The existence of a verrucous area.
C. That the lesions have spread or engrossed during de-
velopment of the disease. 
D. That there has been a recurrence in a previously 
treated area.
E. Histopathologically, there can be from simple epithe-
lial hyperkeratosis to verrucous hyperplasia, verrucous 
carcinoma or oral squamous cell carcinoma, whether in 
situ or infiltrating. 
Minor Criteria (mc):
a. An oral leukoplakia lesion that occupies at least 3 cm 
when adding all the affected areas.
b. That the patient be female.
c. That the patient (male or female) be a non-smoker.
d. A disease evolution higher than 5 years. 
In order to make the diagnosis of PVL, it was suggested 
that one of the two following combinations of the crite-
ria mentioned before were met. 
1. Three major criteria ( being E among them) or
2. Two major criteria (being E among them) + two mi-
nor criteria.
Table 1. PVL case series that complied with our selection criteria and on which we based our diagnostic criteria proposal.
Site: BM (buccal mucosa), G (gingiva), T (tongue) HP (hard palate) L (lip) SP (soft palate), AR (alveolar ridge), FM (floor 
of mouth).
Treatment: RT (radiotherapy), CH (chemotherapy), C (conventional surgery) La (laser), Ret (retinoids), Ex b (excisional 
biopsy), PT (photodynamic therapy), Rs (resection), Ex (excision), Max (maxillectomy), Max p (partial maxillectomy), Stp 
(stripping). 
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Discussion
According to the latest WHO nomenclature, prolifera-
tive verrucous leukoplakia conforms to the new termi-
nology of “potentially malignant disorders” given that 
it is neither a delimited lesion nor a condition (13). PVL 
is known for its aggressive pathology, given its multifo-
cal involvement, tendency to recur after removal, and 
high rate of malignant transformation, which can be 
higher than 70%, reaching 100% in some cases (14-16). 
74.62% of the published cases report a mean malignant 
transformation rate of 6.08 years (14-20). Therefore, the 
early diagnosis of PVL can be beneficial in the prog-
nosis of these patients. Nevertheless, at present, there 
is no criterion that will allow for the early diagnosis of 
the disease.
In previously published series, diagnosis of PVL was 
made according to Hansen’s et al. definition (14). Among 
the cases reported by different authors, certain charac-
teristics tend to recur: a distinct female predilection; a 
mean age at the time of diagnosis of over 60 years; the 
growth and macroscopic changes of lesions; the mas-
ticatory mucosa, gingiva, palate and alveolar ridge as 
the most common sites; a high probability of recurrence 
and a high rate of malignant transformation. Therefore, 
there are several characteristics of the disease which re-
cur or prove to be increasingly more relevant. However, 
no author has systematized these features in the form 
of diagnostic criteria yet. There are only two studies, 
one by Ghazali et al. (22) and another by Gandolfo et al. 
(20), which apply a set of diagnostic criteria to their re-
spective cases, although these are just a transcription of 
Hansen’s definition. Thus, Ghazali et al. (22) establish 
the following criteria:
1. The lesion starts as homogenous leukoplakia without 
evidence of dysplasia at the first visit.
2. With time, some areas of leukoplakia become ver-
rucous.
3. The disease progresses to the development of multi-
ple isolated or confluent lesions at the same or different 
site. 
4. With time, the disease progresses through the differ-
ent histopathological stages reported by Hansen et al. 
(14) (1985).
5. The appearance of new lesions after treatment.
6. A follow-up period of no less than one year.
Ghazali et al. consider that all their proposed criteria 
should be met without exclusion. From their series, only 
three cases were considered doubtful. Yet, all cases 
failed given that the first criterion was not met, since 
the authors had no previous data regarding the appear-
ance of early lesions (22).
On the other hand Gandolfo et al. establish the follow-
ing criteria (20):
1.- An initially innocuous lesion characterized by a ho-
mogenous plaque that progresses over time to an exo-
phytic, diffuse, usually multifocal, lesion with a verru-
cous epithelial growth pattern.
2.- Histopathologically, PVL changes gradually from 
a simple plaque of hyperkeratosis without dysplasia to 
verrucous hyperplasia, verrucous carcinoma or OSSC.
These attempts at establishing a set of criteria are a step 
in the right direction. However, we believe they are in-
sufficient as they don’t take into account the rest of the 
published studies. Although Hansen et al. (14) estab-
lished a comprehensive definition of the disease that has 
served as a starting point, it has not been updated in the 
last two decades. On this basis, the present study pro-
poses a set of criteria based not only in Hansen’s defi-
nition but in the various findings reported in the latter 
published cases of PVL. We have, therefore, identified 
and systematized these findings, or PVL characteristics, 
into major and minor criteria.
On the other hand, in cases of advanced and well-local-
ized PVL, the diagnosis might not be problematic. But 
there are many other situations in which the diagnosis is 
doubtful. With this proposed criteria we aim at helping 
the clinician to establish the earliest possible doubtful 
diagnosis of PVL, as well as to allow for an adequate 
follow-up. We shall comment on the proposed criteria 
below.
Major Criteria.
Major Criterion A: “A leukoplakia lesion with more 
than two different oral sites, which is most frequently 
found in the gingiva, alveolar processes and palate” is 
itself a comprehensive criterion as it refers to the multi-
focality of the lesions on one hand, as well as shows the 
most common site for PVL lesions to date. If we gather 
all the lesions from the different case series, we can ob-
serve that the buccal mucosa is still the most frequently 
involved site (Fig. 1). Nevertheless, the latest published 
case series have reported an increased tendency towards 
PVL lesions settling in keratinized mucosa: gingiva, al-
veolar ridge and hard palate (18-20) (Fig. 2, 3 and 4).
It has been reported that OSCC cases associated to PVL 
develop commonly in these sites (Fig. 5), which are in-
frequent sites for lesions if compared to those of conven-
tional OSCC cases in Western populations: tongue, floor 
of mouth and buccal mucosa (16,18-20,25-28). The pres-
ence of this criterion makes the diagnosis of PVL highly 
doubtful. It is also the criterion that most clinically differ-
entiates this leukoplakia from conventional leukoplakia. 
Major Criteria B, C, and D: Also constitute essential 
characteristics of PVL that are cited in most publica-
tions from Hansen et al. (14) to Gandolfo et al. (20). In 
them, we can see how PVL always progresses towards 
multifocality; the lesion growth; the development of 
verrucous areas, (Fig. 6); and a recurrence rate higher 
than 85%. Given the frequency with which these char-
acteristics occur, we strongly believe they should be 
considered as major criteria (14-20).
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Fig. 1. Location of lesions.
Fig. 2. PVL lesions on keratinized mucosa.
Fig. 3. Multiple lesions at different stages of 
evolution.
Fig.4 . Multiple white lesions next to erythemized 
lesions on the masticatory mucosa.
Fig. 5. Wide lesion with a confirmed diagnosis of 
squamous cell carcinoma. 
Fig. 6. Verrucous aspect of a large lesion which is 
not alone.
Fig. 7. Diagram showing the natural evolution and the various stages 
of the disease (Modified by Greer et al., J Calif Dent Assoc 1999). 
Fig. 8. Note the coexistence of lesions at various 
stages of evolution in the same PVL case.
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Major Criterion E: Histologically, there can be from sim-
ple epithelial hyperkeratosis to verrucous hyperplasia, 
verrucous carcinoma or oral squamous cell carcinoma, 
whether in situ or infiltrating. This criterion is essential 
in order to confirm PVL diagnosis. It has the peculiarity 
of being quite broad given that, from a histological point 
of view, shows the diverse natural evolution of the dis-
ease while also being restrictive: it prevents other white 
or red lesions with a tendency to spread inside the oral 
cavity, such as oral lichen planus, from being diagnosed 
as PVL. In 1985 (14), Hansen explained a histological 
diagram (Fig. 7) with 10 degrees of severity for evalu-
ating the disease (14). Subsequently, Batsakis reduced 
Hansen’s proposal to four stages, eliminating the papil-
lary squamous cell carcinoma, which he considered to 
be independent of PVL, even of the oral cavity where it 
is rarely found, being the oropharynx a more frequent 
site (29).
Therefore, histopathologically, PVL starts as simple 
hyperkeratosis, which can progress to verrucous hyper-
plasia, verrucous carcinoma, and even oral squamous 
cell carcinoma, whether in situ or infiltrating (14,29). 
It should be noted that in cases of multifocality, not all 
lesions are at the same stage of evolution. While one le-
sion may be simple hyperkeratosis, another one located 
elsewhere may already have developed into a carcinoma 
(21,30) (Fig. 8). Thus, various authors suggest a more 
thorough follow-up for these patients, looking out for 
changes in shape, size, colour, as well as the appearance 
of new lesions, carrying out as many biopsies as may be 
needed. (22,23,25,30,31).  
Minor criteria.
Minor criterion a: An oral leukoplakia lesion that occu-
pies at least 3 cm when adding all the affected areas. In 
PVL, we consider that the presence of multiple lesions 
in different sites or the macroscopic alterations is more 
relevant than the size of the lesion itself. Therefore, we 
regard this characteristic as a minor criterion. Nonethe-
less, according to van der Waal and Schepman’s pro-
posal for a modified staging system for oral leukoplakia 
(OLEP), a size larger than 3 cm would be considered 
an eligibility criterion, corresponding to stage II in the 
aforementioned system (32-34). 
Minor criterion b: That the patient be female. Most PVL 
studies report a greater female predilection. In fact, if 
we group all the patients of the different case series, 
we find that women comprise 75.53% (14-20) (Table 1), 
with a ratio of 4:1 (21). As a result, we believe that this 
epidemiological datum should also be regarded as a rel-
evant but minor criterion, given that the disease may 
also be present in men. 
Minor criterion c: That the patient (male or female) be 
a non-smoker. Like in the aforementioned criterion, 
this is a recurrent finding in the different series of pub-
lished cases. As seen from table 1, only the studies by 
Hansen et al. (14) and Zakrzewska et al. (15)  reported 
more smokers than non-smokers, while in the rest of the 
published studies the majority of patients did not smoke 
(14-20). However, the disease is also present in smok-
ers. If we group all the patients of the different studies, 
we find that, in fact, there is no significant difference 
between smokers and non-smokers, given that approxi-
mately 42% smoked (14-20) (Table 1). Therefore, since 
the etiopathogenic role of tobacco in PVL remains un-
clear (16,19,23) and there is no significant difference 
in the occurrence of PVL between smokers and non-
smokers, we believe this datum should be regarded as a 
minor criterion.
Minor criterion d: A disease evolution higher than 5 
years. It is considered minor criteria given that in many 
cases the exact development time cannot be determined. 
Nevertheless, we have established it at a ‘time period 
higher than 5 years’, as the average period of the various 
staging systems of PVL case series is around 6 years 
(14-20) (Table 1).
Conclusions
Proliferative verrucous leukoplakia is a rare but highly 
aggressive form of oral leukoplakia, which requires spe-
cial awareness on the part of the clinician. Therefore, it 
is recommended to have the earliest possible diagnosis, 
as well as consensus on diagnostic criteria to achieve 
uniformity. To this effect, the present study proposes 
a set of criteria, which we believe should be applied to 
case series in order to verify its efficacy.   
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